SC-4289
SC-4289 is a synthetic nonsteroidal estrogen which, along with mytatrienediol (SC-6924; Manvene, Anvene), was developed in the late 1950s as a potential treatment for atherosclerosis in men but was never marketed. The chemical structure of SC-4289 is the same as for methallenestril but differs in that it is the benzyl ether and not the methyl ether.